

**Title:** Renal Denervation for Uncontrolled Hypertension (CAG-00470N)

**Decision:** The Centers for Medicare & Medicaid Services (CMS) is establishing a National Coverage Determination (NCD) to cover radiofrequency renal denervation (rfRDN) and ultrasound renal denervation (uRDN) for uncontrolled hypertension under Coverage with Evidence Development (CED). RDN may be covered for the treatment of uncontrolled hypertension when furnished according to an FDA market-authorized indication, the patient meets all CMS coverage criteria, and the RDN is furnished within a CMS-approved CED study. RDN is not covered for patients outside of a CMS-approved study. Nothing in this NCD would prevent coverage of RDN through NCD 310.1 (Clinical Trial Policy) or through an Investigational Device Exemption (IDE) study.

**What this means:** Coverage of RDN for the treatment of uncontrolled hypertension was previously subject to Medicare Administrative Contractor (MAC) local coverage determinations, when applicable, or at the discretion of HealthPartners. RDN may now be covered for individuals who meet the criteria outlined in the Medicare NCD. Please refer to the final decision memo for all coverage criteria.

**Effective:** October 28, 2025

This announcement can be found at: [Renal Denervation for Uncontrolled Hypertension \(CAG-00470N\)](#)

HealthPartners is a health plan that contracts with both Medicare and the Minnesota Medical Assistance (Medicaid) program to provide benefits of both programs to enrollees. HealthPartners is also a Cost plan and PPO plan with a Medicare contract. Enrollment in HealthPartners depends on contract renewal.

H2462\_90242 IR Approved 06/2015

H2422\_90242 IR Approved 07/2015

H4882\_90242 IR Approved 03/2018